Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Current Infectious Disease Reports

Volumn 20, Issue 8, 2018, Pages

  Nguyen, Lynn ^a   Garcia, Joshua ^b   Gruenberg, Katherine ^a   MacDougall, Conan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MARSHALL B KETCHUM UNIVERSITY   (United States)

Author keywords

Antimicrobial resistance; Multidrug resistant; Newly approved agents; Pipeline antibiotics; Pseudomonas aeruginosa; Treatment

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CEFIDEROCOL; CEFTOLOZANE PLUS TAZOBACTAM; CILASTATIN PLUS IMIPENEM; RELEBACTAM;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG TOXICITY; EPIDEMIOLOGY; HEALTH CARE SYSTEM; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOKINETICS; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 85048157234     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-018-0629-6     Document Type: Review

References (74)

1. Jefferies JMC, Cooper T, Yam T, Clarke SC. Pseudomonas aeruginosa outbreaks in the neonatal intensive care unit—a systematic review of risk factors and environmental sources. J Med Microbiol. 2012;61:1052–61.
2. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–301.
3. • National Healthcare Safety Network. NHSN antibiotic resistance data. CDC website. Available at: https://gis.cdc.gov/grasp/PSA/index.html. Accessed 13 Dec 2017. The CDC provides the current landscape of antimicrobial susceptibilities, showing the growing problem resistance.
4. Strateva T, Yordanov D. Pseudomonas aeruginosa—a phenomenon of bacterial resistance. J Med Microbiol. 2009;58:1133–48.
5. Wolter DJ, Lister PD. Mechanisms of β-lactam resistance among Pseudomonas aeruginosa. Curr Pharm Des. 2013;19:209–22.
6. • Juan C, Moyá B, Pérez JL, Oliver A. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level β-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother. 2006;50:1780–7. Illustrative in vitro study of the regulation of beta-lactamase expression in Pseudomonas and consequences of stable derepression.
7. Drusano GL. Pharmacology of drug resistance. In: Mayers DL, Lerner SA, Ouellette M, Sobel JD, editors. Antimicrobial drug resistance. Totowa: Humana Press; 2009. p. 33–42.
8. Hancock REW, Brinkman FSL. Function of Pseudomonas porins in uptake and efflux. Annu Rev Microbiol. 2002;56:17–38.
9. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 2001;47:247–50.
10. • Patel JB, Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 2017. The current CLSI guidelines give context to the effectiveness of different antibiotics to Pseudomonas aeruginosa.
11. Livermore DM, Yang YJ. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. J Antimicrob Chemother. 1989;24(Suppl A):149–59.
12. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582–610.
13. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis. 2007;45:88–94.
14. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz F-J. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2003;21:409–13.
15. Sainsbury S, Bird L, Rao V, Shepherd SM, Stuart DI, Hunter WN, et al. Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: comparison of native and antibiotic-bound forms. J Mol Biol. 2011;405:173–84.
16. Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71:2713–22.
17. Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN, Sader HS. In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from U.S. medical centers by census region, 2014. Antimicrob Agents Chemother. 2016;60:2537–41.
18. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014;58:1684–92.
19. Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015;59:3656–9.
20. Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from United States medical centers (2011–2014). Diagn Microbiol Infect Dis. 2015;83:389–94.
21. Tominaga N, Edeki T, Li J, Learoyd M, Bouw MR, Das S. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015;21(8):551–8.
22. US Food and Drug Administration Anti-Infective Drugs Advisory Committee. Cerexa, ceftazidime-avibactam for injection,2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf. Accessed 18 Nov 2017.
23. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380–9.
24. Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017;49:579–88.
25. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program. Clin Infect Dis. 2016;63:754–62.
26. Vazquez JA, Patzán LDG, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921–31.
27. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68:1183–92.
28. Avycaz [package insert]. Irvine. GlaxoSmithKline: CA; 2015.
29. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–73.
30. • Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2017; 10.1016/S1473-3099(17)30747-8. This randomized controlled trial evaluates ceftazidime-avibactam as an alternative to meropenem in the treatment of nosocomial pneumonia caused by Gram-negative pathogens, including Pseudomonas aeruginosa.
31. Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49:266–8.
32. Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, et al. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother. 2017;72:2278–89.
33. • van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–41. This is a useful comparative review of the mechanism of action, spectrum of activity, and pharmacokinetics of ceftazidime-avibactam and ceftolozane-tazobactam.
34. Moyá B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933–7.
35. Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, et al. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother. 2012;56:4771–8.
36. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–10.
37. Zerbaxa [package insert]. Syracuse, NY: Merck & Co., Inc; 2014.
38. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56:3086–91.
39. Natesan S, Pai MP, Lodise TP. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. J Antimicrob Chemother. 2017;72:2813–6.
40. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–71.
41. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–56.
42. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65:110–20.
43. Castón JJ, la TÁD, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2017;61:e02136–16.
44. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–5.
45. Patel UC, Nicolau DP, Sabzwari RK. Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane/tazobactam regimen. Infect Dis Ther. 2016;5:73–9.
46. Hernández-Tejedor A, Merino-Vega CD, Martín-Vivas A, de L-GRR, Delgado-Iribarren A, Gabán-Díez Á, et al. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Infection. 2017;45:115–7.
47. Sousa Dominguez A, Perez-Rodríguez MT, Nodar A, Martinez-Lamas L, Perez-Landeiro A, Crespo Casal M. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam. J Antimicrob Chemother. 2017;72:1262–3.
48. Castaldo N, Givone F, Peghin M, Righi E, Sartor A, Bassetti M. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. J Glob Antimicrob Resist. 2017;9:100–2.
49. Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, et al. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy. J Antimicrob Chemother. 2017;72(9):2678–9.
50. Aye C, Williams M, Horvath R. Multidrug resistant Pseudomonas mycotic pseudoaneurysm following cardiac transplant bridged by ventricular assistant device. Case Rep Infect Dis. 2017;2017:1–4. 10.1155/2017/1402320.
51. Peghin M, Maiani M, Castaldo N, Givone F, Righi E, Lechiancole A, et al. Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant. Infection. 2017:1–3.
52. Vickery SB, McClain D, Wargo KA. Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa. Pharmacotherapy. 2016;36:e154–9.
53. Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016;60:3227–31.
54. Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61:e00875–17.
55. Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2017;AAC.01858–17.
56. Page MGP. Siderophore conjugates. Ann N Y Acad Sci. 2013;1277:115–26.
57. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2018;62:e01454–17. 10.1128/AAC.01454-17.
58. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017;61:e00093–17. 10.1128/AAC.00093-17.
59. • Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62:e01968–17. This study describes the in vitro activity of cefiderocol against multidrug-resistant Gram-negative clinical isolates alongside comparator antimicrobials.
60. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, et al. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART Global Surveillance Program). Antimicrob Agents Chemother. 2017;61:e02209–16. 10.1128/AAC.02209-16.
61. Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother. 2016;61:e01381–16. 10.1128/AAC.01381-16.
62. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:7396–401.
63. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2016;71:670–7.
64. Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36:2319–27.
65. Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of humanized exposures of cefiderocol (s-649266) against a diverse population of gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61:e01022–17.
66. Portsmouth S, Van Veenhuyzen D, Echols R, et al. (2017). Poster 1869: Clinical response of cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomized study (APEKS-cUTI). IDWeek 2017, San Diego, CA.
67. Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorg Med Chem Lett. 2014;24:780–5.
68. Livermore DM, Jamrozy D, Mushtaq S, Nichols WW, Young K, Woodford N. AmpC β-lactamase induction by avibactam and relebactam. J Antimicrob Chemother. 2017;72:3342–8.
69. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68:2286–90.
70. Hirsch EB, Ledesma KR, Chang K-T, Schwartz MS, Motyl MR, Tam VH. In vitro activity of mk-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012;56(7):3753–7.
71. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59:5029–31.
72. Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol. 2011;14(5):550–5.
73. • Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:6234–43. This prospective phase II randomized controlled trial determined that imipenem-cilastatin/relebactam was non-inferior to imipenem-cilastatin plus placebo for the treatment of complicated intra-abdominal infections.
74. Sims M, Mariyanovski V, McLeroth P, Akers W, Lee Y-C, Brown ML, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72:2616–26.